ReviewHematology. American Society of Hematology. Education Program2017
Incidental venous thromboembolism: is anticoagulation indicated?
Review in Hematology. American Society of Hematology. Education Program, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.The Cochrane database of systematic reviews · 2020Pooled it
- Deep learning-based algorithm for automatic detection of incidental pulmonary embolism on contrast-enhanced CT: a multicenter multivendor study.Radiology advances · 2025Article
- Radiotherapy-the not-so-insignificant contributor to cancer-associated venous thrombosis.Research and practice in thrombosis and haemostasis · 2025Review
- Catheter replacement combined with antiplatelet therapy in hemodialysis catheter-related right atrial thrombus: a potential treatment approach.BMC cardiovascular disorders · 2025Article
- Clinical characteristic, treatment, and mortality among cancer and non-cancer patients presented with incidental pulmonary embolism.Frontiers in medicine · 2025Article
- Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis.The oncologist · 2024Article
- Incidental deep venous thrombosis diagnosed on lower extremity computed tomography is a rare but clinically impactful finding.Journal of vascular surgery. Venous and lymphatic disorders · 2024Article
- Incidence of venous thromboembolism following head and neck surgery.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023Article
- Rivaroxaban treatment for asymptomatic venous thromboembolism: insights from the J'xactly study.Thrombosis journal · 2023Article
- Validation of the HULL Score clinical prediction rule for unsuspected pulmonary embolism in ambulatory cancer patients.ERJ open research · 2023Article
- The Risk of Venous Thromboembolism in Korean Patients with Breast Cancer: A Single-Center Experience.Cancers · 2023Article
- Prognosis of incidental pulmonary embolism vs. symptomatic pulmonary embolism in cancer patients: a single-center retrospective cohort study in China.Thrombosis journal · 2023Article
- Management and Outcomes of Adults Diagnosed with Acute Pulmonary Embolism in Primary Care: Community-Based Retrospective Cohort Study.Journal of general internal medicine · 2022Article
- Treatment and secondary prophylaxis of venous thromboembolism in cancer patients.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Concomitant Deep Vein Thrombosis in Cancer Patients with Unsuspected Pulmonary Embolism.Cancers · 2022Article
- Long-term exposure to air pollution and risk of venous thromboembolism in a large administrative cohort.Environmental health : a global access science source · 2022Article
- Venous and Arterial Thromboembolism in Patients With Cancer:JACC. CardioOncology · 2021Review
- Clinical factors and outcomes of subsegmental pulmonary embolism in cancer patients.Blood advances · 2021Article
- Prevention and treatment of cancer-associated thrombosis.Current oncology (Toronto, Ont.) · 2020Article
- Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with cancer have a high risk of venous thromboembolism (VTE) and about one-half of these events are incidentally detected. The prognosis of incidental VTE appears to be similar to symptomatic events, with comparably high rates of recurrent VTE in this patient population. In the absence of major contraindications, anticoagulant treatment with low-molecular-weight heparin for 3 to 6 months is generally recommended for incidental proximal deep vein thrombosis as well as for incidental pulmonary embolism that involves multiple subsegmental or more proximal pulmonary arteries. The decision of whether to extend treatment beyond 3 to 6 months should be evaluated on a case-by-case basis after periodic reassessment of the risks factors for bleeding and recurrent VTE while also taking into account patient preferences. The clinical relevance of a single incidental subsegmental pulmonary embolism without concomitant deep vein thrombosis is uncertain and either a watchful approach or a shorter course of anticoagulation to minimize the bleeding risk may also be considered. Preliminary evidence suggests that anticoagulation treatment may be beneficial for cancer patients with incidental distal deep vein thrombosis or incidental splanchnic vein thrombosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.